An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

Inclusion Criteria:

• Participants aged ≥18 and ≤80 years of age at Screening. Where permitted locally,participants 16 to <18 years of age who meet the definition of Tanner Stage 5 fordevelopment

• Confirmed diagnosis of moderately to severely active Crohn's Disease (CD) for atleast 3 months prior to baseline

• Demonstrated inadequate response, have shown loss of response or intolerance toconventional therapies or advanced therapies (ATs)

Exclusion Criteria:

• Participants with Ulcerative Colitis (UC) or indeterminate colitis

• Participants with two entire missing segments of the: terminal ileum, right colontransverse colon, sigmoid and left colon, and rectum

• Prior or current high-grade gastrointestinal (GI) dysplasia

• Participants on treatment with but not on stable doses of conventional therapy priorto baseline

• Participants receiving prohibited medications or therapies

• Participants with previous exposure to anti-TL1A investigational therapy

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.